Deep Blue Medical Advances, Inc.

Deep Blue Medical Advances develops next-generation surgical devices focused on soft tissue surgery and hernia repair. The company's core portfolio includes the T-Line® Hernia Mesh, a novel mesh system designed to address common failure modes in hernia repair, particularly suture pull-through and tissue dehiscence. The T-Line® Hernia Mesh is currently in use in surgical suites across the United States and targets the $1.1 billion global hernia device market. The company is also developing the T-Line® TCS (Tissue Control Suture) for general soft tissue procedures, intended to improve procedure speed, safety, and durability while reducing patient pain from tissue trauma. Additional products under development include the T-Line® Scaffold for breast surgery applications and an Anchor Clip for simplified mesh implantation. The company offers both investigational and commercial-stage devices and is pursuing variants including biosynthetic and coated composite versions of their hernia mesh platform. Deep Blue has been recognized with the 2024 Luis Villalobos Award for Innovative Company of the Year in Life Sciences, indicating clinical and market validation of their surgical technology approach.